Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP4 | Q02790 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PSMB9 | P28065 | 3/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491513 | 1.00 | FKBP4 (0.52) | FKBP4CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL5490069 | 0.98 | FKBP4 (0.50) | FKBP4CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL28572673 | 0.92 | FKBP4 (0.50) | FKBP4CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL15624155 | 0.88 | FKBP4 (0.46) | FKBP4CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL5491076 | 0.88 | CYP2C19 (0.44) | FKBP4CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL5491087 | 0.88 | CYP2C19 (0.44) | FKBP4CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL15624120 | 0.86 | FKBP4 (0.44) | FKBP4CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL15624125 | 0.86 | FKBP4 (0.44) | FKBP4CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL11348866 | 0.86 | FKBP4 (0.45) | FKBP4CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL5490071 | 0.86 | CYP2C19 (0.45) | FKBP4CYP2C19MAPTCYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1743884-A1 | Progrugs to d-prolines | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | claimed |
| US-6903129-B2 | D-proline prodrugs | HOFFMAN-LA ROCHE INC. (US) | 2005-06-07 | — | — | US | claimed |
| EP-1458680-A1 | PRODRUGS TO D-PROLINES | F. Hoffmann-La Roche AG (CH) | 2004-09-22 | — | — | EP | claimed |
| US-20030134891-A1 | New D-proline prodrugs | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-07-17 | — | — | US | claimed |
| WO-2003051836-A1 | PRODRUGS TO D-PROLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | WO | claimed |
| EP-1743884-A1 | Progrugs to d-prolines | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| US-6903129-B2 | D-proline prodrugs | HOFFMAN-LA ROCHE INC. (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1458680-A1 | PRODRUGS TO D-PROLINES | F. Hoffmann-La Roche AG (CH) | 2004-09-22 | — | — | EP | disclosed |
| US-20030134891-A1 | New D-proline prodrugs | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-07-17 | — | — | US | disclosed |
| WO-2003051836-A1 | PRODRUGS TO D-PROLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134891-A1 | New D-proline prodrugs | PCNP, PREP, APP | FKBP4 351/4885CYP2C19 1676/4885MAPT 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.